KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Other Preferred Equity: 2015-2016

Historic Other Preferred Equity for Teva Pharmaceutical Industries (TEVA) over the last 2 years, with Dec 2016 value amounting to $3.6 billion.

  • Teva Pharmaceutical Industries' Other Preferred Equity changed negligibly% to $3.6 billion in Q3 2017 from the same period last year, while for Sep 2017 it was $3.6 billion, marking a year-over-year negligible change of negligibly%. This contributed to the annual value of $3.6 billion for FY2016, which is 10.00% up from last year.
  • Teva Pharmaceutical Industries' Other Preferred Equity amounted to $3.6 billion in FY2016, which was up 10.00% from $3.3 billion recorded in FY2015.
  • In the past 5 years, Teva Pharmaceutical Industries' Other Preferred Equity ranged from a high of $3.6 billion in FY2016 and a low of $3.3 billion during FY2015.
  • For the 2-year period, Teva Pharmaceutical Industries' Other Preferred Equity averaged around $3.5 billion, with its median value being $3.5 billion (2015).
  • Data for Teva Pharmaceutical Industries' Other Preferred Equity shows a peak YoY increased of 10.00% (in 2016) over the last 5 years.
  • Over the past 2 years, Teva Pharmaceutical Industries' Other Preferred Equity (Yearly) stood at $3.3 billion in 2015, then grew by 10.00% to $3.6 billion in 2016.